Phase 0 1 trial
Phase 0
NCT07706205 Sep 2026 → Dec 2027 expected blood group incompatibility West China Hospital
Not yet recruiting
No outcome recorded
Phase 1 8 trials
Phase 1
NCT07332507 Mar → Dec 2027 expected plasmablastic lymphoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT07581704 Jun 2026 → Jun 2029 expected plasma cell myeloma Christopher Strouse
Recruiting
No outcome recorded
Phase 1
NCT07105059 Aug 2025 → Aug 2028 expected plasma cell myeloma Memorial Sloan Kettering Cancer Center
Recruiting
No outcome recorded
Phase 1
NCT06425991 Jun 2024 → Jun 2025 overdue plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT05338775 May 2022 → May 2025 overdue refractory plasma cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT04722146 Mar 2021 → Oct 2025 overdue plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT04108195 Feb 2020 → Apr 2027 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT03145181 May 2017 → Sep 2025 overdue hematopoietic and lymphoid cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1/2 4 trials
Phase 1/2
NCT07463807 Jul → Aug 2026 overdue plasma cell myeloma National Cancer Institute (NCI)
Not yet recruiting
No outcome recorded
Phase 1/2
NCT07099391 Jul 2025 → Jul 2029 expected plasma cell myeloma Memorial Sloan Kettering Cancer Center
Recruiting
No outcome recorded
Phase 1/2
NCT04696809 Feb 2021 → Apr 2026 hematopoietic and lymphoid cell neoplasm Janssen Pharmaceutical K.K.
Completed
No outcome recorded
Phase 1/2
NCT04586426 Dec 2020 → Mar 2025 overdue plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2 25 trials
Phase 2
NCT07631208 Oct 2026 → Jan 2027 expected interstitial lung disease Assistance Publique - Hôpitaux de Paris
Not yet recruiting
No outcome recorded
Phase 2
NCT06948084 Aug 2026 → Feb 2028 expected plasma cell myeloma National Cancer Institute (NCI)
Not yet recruiting
No outcome recorded
Phase 2
NCT07605416 Jul 2026 → Nov 2032 expected plasma cell leukemia National Cancer Institute (NCI)
Not yet recruiting
No outcome recorded
Phase 2
NCT07029776 Jul 2026 → Apr 2030 expected plasma cell myeloma University of Arkansas
Not yet recruiting
No outcome recorded
Phase 2
NCT07638683 May 2026 → Jul 2028 expected AL amyloidosis , plasma cell myeloma Shanghai Zhongshan Hospital
Recruiting
No outcome recorded
Phase 2
NCT07107529 Dec 2025 → Apr 2029 expected plasma cell myeloma European Myeloma Network B.V.
Recruiting
No outcome recorded
Phase 2
NCT07110844 Nov 2025 → Oct 2031 expected AL amyloidosis Rajshekhar Chakraborty, MD
Recruiting
No outcome recorded
Phase 2
NCT06880601 Nov 2025 → Nov 2029 expected plasma cell myeloma GIMEMA Foundation
Not yet recruiting
No outcome recorded
Phase 2
NCT06993675 Aug 2025 → Aug 2029 expected plasma cell myeloma Noffar Bar
Recruiting
No outcome recorded
Phase 2
NCT06649695 Jul 2025 → Sep 2028 expected AL amyloidosis European Myeloma Network B.V.
Active not recruiting
No outcome recorded
Phase 2
NCT07079423 Jun 2025 → Jan 2027 expected AL amyloidosis Peking Union Medical College Hospital
Recruiting
No outcome recorded
Phase 2
NCT06935162 May 2025 → Dec 2026 expected AL amyloidosis Peking Union Medical College Hospital
Recruiting
No outcome recorded
Phase 2
NCT06758375 Mar 2025 → Sep 2026 expected plasma cell myeloma Hospital Universitario Dr. Jose E. Gonzalez
Recruiting
No outcome recorded
Phase 2
NCT06171685 Nov 2024 → Jul 2029 expected plasma cell myeloma Multiple Myeloma Research Consortium
Active not recruiting
No outcome recorded
Phase 2
NCT06577025 Aug 2024 → Sep 2030 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2
NCT06353022 Jun 2024 → Apr 2028 expected plasma cell myeloma Nantes University Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT06505369 Jun 2024 → Nov 2026 expected plasma cell myeloma North Estonia Medical Centre
Recruiting
No outcome recorded
Phase 2
NCT05572229 Dec 2023 → Apr 2026 overdue plasma cell myeloma University Hospital, Lille
Recruiting
No outcome recorded
Phase 2
NCT05231629 Dec 2023 → Dec 2027 expected plasma cell myeloma University of Alabama at Birmingham
Recruiting
No outcome recorded
Phase 2
NCT06100237 Dec 2023 → Dec 2028 expected plasma cell myeloma Carl Ola Landgren, MD, PhD
Recruiting
No outcome recorded
Phase 2
NCT05972135 Oct 2023 → Aug 2027 expected plasma cell myeloma SCRI Development Innovations, LLC
Recruiting
No outcome recorded
Phase 2
NCT05849610 Sep 2023 → Mar 2026 overdue —
PETHEMA Foundation
Active not recruiting
No outcome recorded
Phase 2
NCT05695508 Dec 2022 → Sep 2028 expected plasma cell myeloma University of Heidelberg Medical Center
Recruiting
No outcome recorded
Phase 2
NCT05469893 Aug 2022 → Jul 2030 expected smoldering plasma cell myeloma Irene Ghobrial, MD
Recruiting
No outcome recorded
Phase 2
NCT04557098 Sep 2020 → Nov 2021 overdue hematopoietic and lymphoid cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Show 15 more trials Phase 3 7 trials
Phase 3
NCT07649525 Jul 2026 → Jun 2033 expected plasma cell leukemia , plasma cell myeloma University of Leeds
Recruiting
No outcome recorded
Phase 3
NCT07671287 Jun 2026 → Feb 2031 expected plasma cell myeloma University of Heidelberg Medical Center
Not yet recruiting
No outcome recorded
Phase 3
NCT06208150 Jan 2024 → Apr 2026 overdue plasma cell myeloma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT05572515 Mar 2023 → Oct 2025 overdue refractory plasma cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 3
NCT05552222 Oct 2022 → Apr 2031 expected plasma cell myeloma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT05243797 Sep 2022 → Apr 2028 expected plasma cell myeloma European Myeloma Network B.V.
Recruiting
No outcome recorded
Phase 3
NCT05083169 Oct 2021 → Dec 2028 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 4 4 trials
Phase 4
NCT07474961 Mar 2027 → Dec 2036 expected Waldenstrom macroglobulinemia , plasma cell myeloma Anne Louise Tølbøll Sørensen
Not yet recruiting
No outcome recorded
Phase 4
NCT07689149 Jun 2026 → Dec 2029 expected anti-HLA hyperimmunization , disease related to solid organ transplantation West China Hospital
Not yet recruiting
No outcome recorded
Phase 4
NCT07030517 May 2025 → Nov 2026 expected plasma cell myeloma Johnson & Johnson Private Limited
Recruiting
No outcome recorded
Phase 4
NCT06251076 Nov 2024 → Jun 2026 overdue plasma cell myeloma , refractory malignant neoplasm University Health Network, Toronto
Recruiting
No outcome recorded
Phase not applicable 1 trial
— NCT06699394 Mar → Dec 2025 overdue AL amyloidosis Peking University People's Hospital
Recruiting
No outcome recorded
Phase not stated 2 trials
— NCT05463939 — refractory plasma cell neoplasm Janssen Research & Development, LLC
Approved for marketing
No outcome recorded
— NCT05161598 — plasma cell myeloma Janssen Research & Development, LLC
No longer available
No outcome recorded